Ethiopian Pharmaceutical Manufacturing Sh. Co.

epharmsc.com

The Ethiopian Pharmaceuticals Manufacturing Sh. Co. (EPHARM) is a pioneer in the pharmaceutical manufacturing industry of Ethiopia. It is now 52 years old. It had been the only pharmaceutical manufacturer for more than 36 years in the country. It’s headquarter is located in Nifas Silk Lafto subcity, Addis Ababa. EPHARM is currently producing different dosage forms, which makes it peculiar from many of the local pharmaceutical manufacturers. EPHARM has been producing high quality and affordable medicine that have addressed the critical health problems of the Ethiopian people for more than fifty years. The products encompass; Antibiotics, Infusions, Topical drugs, Drugs that act on central nervous system (CNS), Gastroenterological drugs, Vitamins, Anti-Allergic, Analgesics, Anti- Tussives and many more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

PIRAMAL PHARMA SOLUTIONS ANNOUNCES STERILE FILL/FINISH PROGRAM THERATECHNOLOGIES INC

Piramal Pharma Solutions, Theratechnologies Inc. | January 25, 2021

news image

Piramal Pharma Limited's Pharma Solutions business, a leading contract development and manufacturing organization (CDMO), today declared that it is giving Theratechnologies Inc. with GMP manufacturing of sterile fill/finish drug item to help their developmental item as it goes into a first-in-people clinical investigation. The clinical material is being created at the Piramal Pharma Solutions (PPS) manufacturing site in Lexington, Kentucky, which is perceived around the world ...

Read More

APRICUS HEALTH PARTNERS WITH MEDICARE ADVANTAGE PLAN DEVOTED HEALTH AND FULL-SERVICE RETAIL PHARMACY LITON RX

Apricus Health | November 04, 2020

news image

Apricus Health, an innovative healthcare company delivering high impact, relationship-based care, today announced two new partnerships that provide its members with extraordinary services. Medicare Advantage plan provider Devoted Health and full-service retail pharmacy Liton Rx are now partnering with the Apricus Health Network which is designed by Arizona physicians. "We are committed to helping our members with a range of quality services to improve health outcomes and significantly...

Read More

Pharmacy Market

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS

FogPharma | November 28, 2022

news image

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset...

Read More

U.S. FDA ALLOWS PRIORITY REVIEW TO NEW DRUG APPLICATION FOR VERICIGUAT TREATING CHRONIC HEART FAILURE

Merck | July 17, 2020

news image

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in combination with ...

Read More
news image

Pharma Tech

PIRAMAL PHARMA SOLUTIONS ANNOUNCES STERILE FILL/FINISH PROGRAM THERATECHNOLOGIES INC

Piramal Pharma Solutions, Theratechnologies Inc. | January 25, 2021

Piramal Pharma Limited's Pharma Solutions business, a leading contract development and manufacturing organization (CDMO), today declared that it is giving Theratechnologies Inc. with GMP manufacturing of sterile fill/finish drug item to help their developmental item as it goes into a first-in-people clinical investigation. The clinical material is being created at the Piramal Pharma Solutions (PPS) manufacturing site in Lexington, Kentucky, which is perceived around the world ...

Read More
news image

APRICUS HEALTH PARTNERS WITH MEDICARE ADVANTAGE PLAN DEVOTED HEALTH AND FULL-SERVICE RETAIL PHARMACY LITON RX

Apricus Health | November 04, 2020

Apricus Health, an innovative healthcare company delivering high impact, relationship-based care, today announced two new partnerships that provide its members with extraordinary services. Medicare Advantage plan provider Devoted Health and full-service retail pharmacy Liton Rx are now partnering with the Apricus Health Network which is designed by Arizona physicians. "We are committed to helping our members with a range of quality services to improve health outcomes and significantly...

Read More
news image

Pharmacy Market

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS

FogPharma | November 28, 2022

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset...

Read More
news image

U.S. FDA ALLOWS PRIORITY REVIEW TO NEW DRUG APPLICATION FOR VERICIGUAT TREATING CHRONIC HEART FAILURE

Merck | July 17, 2020

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in combination with ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us